We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Whooping Cough Rates Raise Questions About Vaccine

By HospiMedica International staff writers
Posted on 09 Aug 2012
The rising rate of whooping cough cases in the United States may signal the reduced efficacy of the acellular pertussis vaccine, according to a new report.

Researchers at the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) reported a gradual and sustained increase in pertussis since historic lows in the 1970s, with the last peak year being 2010, with 27,000 reported cases and 27 deaths, 25 of them infants. More...
Since mid-2011, a substantial rise in pertussis cases has been reported in the state of Washington, with the reported number of cases by June 2012 reaching 2,520, a 1,300% increase compared with the same period in 2011, and the highest number of cases reported in any year since 1942.

These figures are consistent with national trends, with high rates of pertussis observed among infants aged younger than one year and children aged 10 years. However, the incidence in adolescents aged 13-14 years also was increased, despite high rates of vaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. According to the researchers, the increase in pertussis among these, who received only the acellular pertussis vaccine, and not the whole-cell version, suggests a waning of the vaccine. The report was published in the July 20, 2012, issue of Morbidity & Mortality Weekly Report.

“The highest rates are in infants under a year old, with half of cases occurring in infants younger than 3 months who couldn't yet be vaccinated; nine infant deaths have been reported,” said Anne Schuchat, MD, director of the National Center for Immunization and Respiratory Diseases at the CDC. “Their immunity depends on that of the people around them. All pregnant women and other people who are going to come in contact with infants -- grandparents and healthcare professionals, for instance -- should receive the Tdap booster.”

The switch from whole-cell pertussis to acellular pertussis was made in 1997, due to concerns over a possible (though unproven) link to chronic neurologic problems, as well as more severe injection-site reactions and fever. Today, children receive a five-dose series of the DTaP vaccination beginning at age 2 months, followed by a booster Tdap shot at age 11 or 12.

Related Links:

US Centers for Disease Control and Prevention





Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.